RhAPPcast podcast

Medication Review: Guselkumab Label Updates Secondary to Data From the APEX and SOLSTICE Studies

10/13/2026
0:00
4:32
Rewind 15 seconds
Fast Forward 15 seconds

In this medication review, Amanda Mixon, PA-C, reviews the APEX and SOLSTICE clinical trials and their implications for guselkumab (Tremfya) in active psoriatic arthritis (PsA). This overview highlights the role of IL-23 inhibition in psoriatic arthritis management, including the APEX findings that supported a U.S. prescribing information update addressing inhibition of structural joint damage.

This episode explores the APEX data on radiographic progression and the SOLSTICE findings in patients with an inadequate response or intolerance to prior tumor necrosis factor (TNF) inhibitor therapy. Amanda discusses key outcomes across joint symptoms, physical function, enthesitis, dactylitis, skin psoriasis, and minimal disease activity, along with the reported safety findings. The discussion emphasizes how these studies may inform treatment sequencing and conversations about symptom control, joint preservation, and individualized treatment goals.

Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and other clinicians managing psoriatic arthritis, this module offers practical insights into guselkumab clinical trial data, structural damage prevention, and shared decision-making when selecting biologic therapy. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP Content Rheum, or the RhAPP ACE 2.0 app.

More episodes from "RhAPPcast"